Symphogen publishes discovery and pre-clinical data on first chicken-derived antibody to enter human clinical trials Sym021 a novel anti-PD1 compound currently in Phase 1 clinical trials Copenhagen, 16 May 2019 – Symphogen, a private clinical stage oncology focused biopharmaceutical company with a productive...

Symphogen announces new capital raise and explores strategic options Copenhagen, 15 May 2019 – Today, Symphogen called for an ordinary shareholders meeting to be held on 29 May 2019. At the meeting, Symphogen’s Board of Directors will propose to raise new capital...